2026/03/02 更新

写真a

ユラ ヨシミツ
由良 義充
Yoshimitsu Yura
所属
医学部附属病院 循環器内科 病院助教
職名
病院助教

学位 1

  1. 博士(医学) ( 2016年9月   名古屋大学 ) 

研究キーワード 3

  1. クローン性造血

  2. 心血管疾患

  3. 腫瘍循環器学

研究分野 1

  1. ライフサイエンス / 循環器内科学

経歴 6

  1. 名古屋大学   高等研究院   兼任教員

    2023年4月 - 現在

  2. 国立研究開発法人科学技術振興機構 創発研究者   兼任教員

    2023年4月 - 現在

  3. 名古屋大学医学部附属病院   循環器内科   病院助教

    2021年10月 - 現在

  4. バージニア大学医学部   循環器内科   助教

    2021年5月 - 2021年9月

      詳細を見る

    国名:アメリカ合衆国

  5. バージニア大学医学部   心血管研究所   博士研究員

    2018年4月 - 2021年4月

      詳細を見る

    国名:アメリカ合衆国

  6. ボストン大学医学部   血管生物学部門   博士研究員

    2017年4月 - 2018年3月

      詳細を見る

    国名:アメリカ合衆国

▼全件表示

学歴 2

  1. 名古屋大学   医学部   医学系研究科

    2012年4月 - 2016年3月

      詳細を見る

    国名: 日本国

  2. 名古屋大学   医学部   医学科

    2001年4月 - 2007年3月

      詳細を見る

    国名: 日本国

所属学協会 3

  1. 日本腫瘍循環器学会

    2024年4月 - 現在

  2. 日本循環器学会

  3. 日本内科学会

委員歴 6

  1. JCS-COMPASS, Core Faculty  

    2024年7月 - 現在   

  2. 日本循環器学会   BCVR基礎研究部会 オブザーバー  

    2024年6月 - 現在   

  3. 日本循環器学会東海支部   若手委員会, 委員長  

    2021年11月 - 現在   

      詳細を見る

    団体区分:学協会

  4. ISHR U45   Section Leaders of U45-ISHR Japanese Section  

    2021年6月 - 現在   

  5. JCS-COMPASS Core Faculty  

    2024年7月 - 現在   

  6. BCVR基礎研究部会   オブザーバー  

    2024年6月 - 現在   

▼全件表示

受賞 8

  1. 第13回万有医学奨励賞 最優秀賞

    2024年12月   MSD生命科学財団  

  2. 研究奨励賞

    2024年6月   日本心血管協会   免疫細胞の遺伝子変異に着目した HFpEF の新規病態解明

    由良 義充

     詳細を見る

    受賞区分:国内学会・会議・シンポジウム等の賞  受賞国:日本国

  3. 日本細胞生物学会論文賞

    2017年5月   日本細胞生物学会  

    由良 義充

  4. 日本細胞生物学会優秀発表賞

    2015年6月   日本細胞生物学会  

    由良 義充

  5. 日本薬理学会優秀発表賞

    2015年3月   日本薬理学会  

    由良 義充

  6. 第13回万有医学奨励賞 最優秀賞

    2024年12月   MSD生命科学財団  

    由良 義充

  7. 研究奨励賞

    2024年5月   日本心血管協会  

    由良 義充

  8. 宮田心臓病研究振興基金奨励賞

    2022年3月   宮田心臓病研究振興基金  

    由良 義充

▼全件表示

 

論文 44

  1. Tet2-driven clonal hematopoiesis drives aortic aneurysm via macrophage-to-osteoclast-like differentiation. 査読有り Open Access

    Yonekawa J, Yura Y, Luo J, Kato K, Ikeda S, Kawai Y, Hattori T, Okamoto R, Kizuki Mari, Yura-Miura E, Horitani K, Min KD, Emoto T, Banno H, Takefuji M, Walsh K, Murohara T.

    The Journal of clinical investigation     2026年2月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1172/JCI198708

    Open Access

  2. Hematopoietic loss of Y chromosome activates immune checkpoints and contributes to impaired senescent cell clearance and renal disease 査読有り 国際誌 Open Access

    Arai, Y; Chavkin, NW; Arai, Y; Halvardson, J; Bjurling, J; Doviak, H; Cochran, JD; Evans, MA; Horitani, K; Yura, Y; Miura-Yura, E; Sano, S; Forsberg, LA; Walsh, K

    SCIENCE TRANSLATIONAL MEDICINE   17 巻 ( 810 ) 頁: eadv4071   2025年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Science Translational Medicine  

    The accumulation of senescent cells contributes to morbidity and mortality; however, common mechanisms underpinning this age-associated phenomenon remain elusive. Hematopoietic loss of the Y chromosome (LOY) is the most frequently acquired somatic mutation in males, and this condition has been associated with various age-associated diseases and reduced lifespan. Therefore, we investigated the role of hematopoietic LOY in promoting cellular senescence, focusing on kidney disease because of its well-documented connection with aging and senescence. Herein, a prospective cohort study revealed that LOY in blood is associated with an increased incidence of kidney diseases. Analyses of transcriptional signatures in human kidneys found that immune cell LOY is enriched in patients with kidney disease and associated with greater amounts of cellular senescence. In male mice reconstituted with bone marrow lacking the Y chromosome, renal dysfunction was accompanied by senescent cell accumulation in models of kidney injury and advanced age. Treatment with a senolytic agent promoted senolysis and preferentially inhibited the progression of renal dysfunction in LOY mice. Hematopoietic LOY led to up-regulation of multiple immune inhibitory receptors, and treatment with the combination of antibodies targeting PD-1 (programmed cell death protein 1) and SIRPα (signal regulatory protein α) reduced senescent cell accumulation and rescued the renal pathology conferred by hematopoietic LOY in the kidney injury model. Collectively, these data indicate that hematopoietic LOY contributes to pathological conditions by impairing the clearance of senescent cells through up-regulation of immune checkpoint proteins.

    DOI: 10.1126/scitranslmed.adv4071

    Web of Science

    Scopus

    PubMed

  3. Experimental TET2 Clonal Hematopoiesis Predisposes to Renal Hypertension Through an Inflammasome-Mediated Mechanism 査読有り 国際誌 Open Access

    Polizio, AH; Marino, L; Min, KD; Yura, Y; Rolauer, L; Cochran, JD; Evans, MA; Park, E; Doviak, H; Miura-Yura, E; Good, ME; Wolpe, AG; Grandoch, M; Isakson, BE; Walsh, K

    CIRCULATION RESEARCH   135 巻 ( 9 ) 頁: 933 - 950   2024年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Circulation Research  

    BACKGROUND: Hypertension incidence increases with age and represents one of the most prevalent risk factors for cardiovascular disease. Clonal events in the hematopoietic system resulting from somatic mutations in driver genes are prevalent in elderly individuals who lack overt hematologic disorders. This condition is referred to as age-related clonal hematopoiesis (CH), and it is a newly recognized risk factor for cardiovascular disease. It is not known whether CH and hypertension in the elderly are causally related and, if so, what are the mechanistic features. METHODS: A murine model of adoptive bone marrow transplantation was employed to examine the interplay between Tet2 (ten-eleven translocation methylcytosine dioxygenase 2) clonal hematopoiesis and hypertension. RESULTS: In this model, a subpressor dose of Ang II (angiotensin II) resulted in elevated systolic and diastolic blood pressure as early as 1 day after challenge. These conditions led to the expansion of Tet2-deficient proinflammatory monocytes and bone marrow progenitor populations. Tet2 deficiency promoted renal CCL5 (C-C motif ligand 5) chemokine expression and macrophage infiltration into the kidney. Consistent with macrophage involvement, Tet2 deficiency in myeloid cells promoted hypertension when mice were treated with a subpressor dose of Ang II. The hematopoietic Tet2<sup>-/-</sup>condition led to sodium retention, renal inflammasome activation, and elevated levels of IL (interleukin)-1β and IL-18. Analysis of the sodium transporters indicated NCC (sodium-chloride symporter) and NKCC2 (Na<sup>+</sup>-K<sup>+</sup>-Cl<sup>-</sup>cotransporter 2) activation at residues Thr53 and Ser105, respectively. Administration of the NLRP3 (NLR family pyrin domain containing 3) inflammasome inhibitor MCC950 reversed the hypertensive state, sodium retention, and renal transporter activation. CONCLUSIONS: Tet2-mediated CH sensitizes mice to a hypertensive stimulus. Mechanistically, the expansion of hematopoietic Tet2-deficient cells promotes hypertension due to elevated renal immune cell infiltration and activation of the NLRP3 inflammasome, with consequences on sodium retention. These data indicate that carriers of TET2 CH could be at elevated risk for the development of hypertension and that immune modulators could be useful in treating hypertension in this patient population. 2024 American Heart Association, Inc.

    DOI: 10.1161/CIRCRESAHA.124.324492

    Web of Science

    Scopus

    PubMed

  4. Disruption of the <i>Uty</i> epigenetic regulator locus in hematopoietic cells phenocopies the profibrotic attributes of Y chromosome loss in heart failure 査読有り 国際誌 Open Access

    Horitani, K; Chavkin, NW; Arai, Y; Wang, Y; Ogawa, H; Yura, Y; Evans, MA; Cochran, JD; Thel, MC; Polizio, AH; Sano, M; Miura-Yura, E; Arai, Y; Doviak, H; Arnold, AP; Gelfand, BD; Hirschi, KK; Sano, S; Walsh, K

    NATURE CARDIOVASCULAR RESEARCH   3 巻 ( 3 ) 頁: 343 - 355   2024年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Nature Cardiovascular Research  

    Heart failure affects millions of people worldwide, with men exhibiting a higher incidence than women. Our previous work has shown that mosaic loss of the Y chromosome (LOY) in leukocytes is causally associated with an increased risk for heart failure. Here, we show that LOY macrophages from the failing hearts of humans with dilated cardiomyopathy exhibit widespread changes in gene expression that correlate with cardiac fibroblast activation. Moreover, we identify the ubiquitously transcribed tetratricopeptide Y-linked (Uty) gene in leukocytes as a causal locus for an accelerated progression of heart failure in male mice with LOY. We demonstrate that Uty disruption leads to epigenetic alterations in both monocytes and macrophages, increasing the propensity of differentiation into profibrotic macrophages. Treatment with a transforming growth factor-β-neutralizing antibody prevented the cardiac pathology associated with Uty deficiency in leukocytes. These findings shed light on the mechanisms that contribute to the higher incidence of heart failure in men.

    DOI: 10.1038/s44161-024-00441-z

    Open Access

    Web of Science

    Scopus

    PubMed

  5. Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction 査読有り 国際共著 国際誌 Open Access

    Cochran, JD; Yura, Y; Thel, MC; Doviak, H; Polizio, AH; Arai, Y; Arai, Y; Horitani, K; Park, E; Chavkin, NW; Kour, A; Sano, S; Mahajan, N; Evans, M; Huba, M; Naya, NM; Sun, H; Ban, YH; Hirschi, KK; Toldo, S; Abbate, A; Druley, TE; Ruberg, FL; Maurer, MS; Ezekowitz, JA; Dyck, JRB; Walsh, K

    CIRCULATION   148 巻 ( 15 ) 頁: 1165 - 1178   2023年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Circulation  

    BACKGROUND: Clonal hematopoiesis (CH), which results from an array of nonmalignant driver gene mutations, can lead to altered immune cell function and chronic disease, and has been associated with worse outcomes in patients with heart failure (HF) with reduced ejection fraction. However, the role of CH in the prognosis of HF with preserved ejection fraction (HFpEF) has been understudied. This study aimed to characterize CH in patients with HFpEF and elucidate its causal role in a murine model. METHODS: Using a panel of 20 candidate CH driver genes and a variant allele fraction cutoff of 0.5%, ultradeep error-corrected sequencing identified CH in a cohort of 81 patients with HFpEF (mean age, 71±6 years; ejection fraction, 63±5%) and 36 controls without a diagnosis of HFpEF (mean age, 74±7 years; ejection fraction, 61.5±8%). CH was also evaluated in a replication cohort of 59 individuals with HFpEF. RESULTS: Compared with controls, there was an enrichment of TET2-mediated CH in the HFpEF patient cohort (12% versus 0%, respectively; P=0.02). In the HFpEF cohort, patients with CH exhibited exacerbated diastolic dysfunction in terms of E/e′ (14.9 versus 11.7, respectively; P=0.0096) and E/A (1.69 versus 0.89, respectively; P=0.0206) compared with those without CH. The association of CH with exacerbated diastolic dysfunction was corroborated in a validation cohort of individuals with HFpEF. In accordance, patients with HFpEF, an age ≥70 years, and CH exhibited worse prognosis in terms of 5-year cardiovascular-related hospitalization rate (hazard ratio, 5.06; P=0.042) compared with patients with HFpEF and an age ≥70 years without CH. To investigate the causal role of CH in HFpEF, nonconditioned mice underwent adoptive transfer with Tet2-wild-type or Tet2-deficient bone marrow and were subsequently subjected to a high-fat diet/L-NAME (N<inf>ω</inf>-nitro-l-arginine methyl ester) combination treatment to induce features of HFpEF. This model of Tet2-CH exacerbated cardiac hypertrophy by heart weight/tibia length and cardiomyocyte size, diastolic dysfunction by E/e′ and left ventricular end-diastolic pressure, and cardiac fibrosis compared with the Tet2-wild-type condition. CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.

    DOI: 10.1161/CIRCULATIONAHA.123.064170

    Web of Science

    Scopus

    PubMed

  6. Therapy-Related Clonal Hematopoiesis A New Link Between Cancer and Cardiovascular Disease 査読有り 国際誌 Open Access

    Yura, Y; Cochran, JD; Walsh, K

    HEART FAILURE CLINICS   18 巻 ( 3 ) 頁: 349 - 359   2022年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Heart Failure Clinics  

    DOI: 10.1016/j.hfc.2022.02.010

    Web of Science

    Scopus

    PubMed

  7. The Cancer Therapy-Related Clonal Hematopoiesis Driver Gene <i>Ppm1d</i> Promotes Inflammation and Non-Ischemic Heart Failure in Mice 査読有り 国際誌 Open Access

    Yura, Y; Miura-Yura, E; Katanasaka, Y; Min, YD; Chavkin, N; Polizio, AH; Ogawa, H; Horitani, K; Doviak, H; Evans, MA; Sano, M; Wang, Y; Boroviak, K; Philippos, G; Domingues, AF; Vassiliou, G; Sano, S; Walsh, K

    CIRCULATION RESEARCH   129 巻 ( 6 ) 頁: 684 - 698   2021年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Circulation Research  

    Rationale: Cancer therapy can be associated with short- and long-term cardiac dysfunction. Patients with cancer often exhibit therapy-related clonal hematopoiesis (t-CH), an aggressive form of clonal hematopoiesis that can result from somatic mutations in genes encoding regulators of the DNA-damage response (DDR) pathway. Gain-of-function mutations in exon 6 of the protein phosphatase Mg2+/Mn2+ dependent 1D (PPM1D) gene are the most frequently mutated DNA-damage response gene associated with t-CH. Whether t-CH can contribute to cardiac dysfunction is unknown. Objective: We evaluated the causal and mechanistic relationships between Ppm1d-mediated t-CH and nonischemic heart failure in an experimental system. Methods and Results: To test whether gain-of-function hematopoietic cell mutations in Ppm1d can increase susceptibility to cardiac stress, we evaluated cardiac dysfunction in a mouse model where clonal hematopoiesis-associated mutations in exon 6 of Ppm1d were produced by CRISPR-Cas9 technology. Mice transplanted with hematopoietic stem cells containing the mutated Ppm1d gene exhibited augmented cardiac remodeling following the continuous infusion of Ang II (angiotensin II). Ppm1d-mutant macrophages were impaired in DDR pathway activation and displayed greater DNA damage, higher reactive oxygen species generation, and an augmented proinflammatory profile with elevations in IL (interleukin)-1β and IL-18. The administration of an NLRP3 (NLR family pyrin domain containing 3) inflammasome inhibitor to mice reversed the cardiac phenotype induced by the Ppm1d-mutated hematopoietic stem cells under conditions of Ang II-induced stress. Conclusions: A mouse model of Ppm1d-mediated t-CH was more susceptible to cardiac stress. Mechanistically, disruption of the DDR pathway led to elevations in inflammatory cytokine production, and the NLRP3 inflammasome was shown to be essential for this augmented cardiac stress response. These data indicate that t-CH involving activating mutations in PPM1D can contribute to the cardiac dysfunction observed in cancer survivors, and that anti-inflammatory therapy may have utility in treating this condition.

    DOI: 10.1161/CIRCRESAHA.121.319314

    Open Access

    Web of Science

    Scopus

    PubMed

  8. <i>Tet2</i>-mediated clonal hematopoiesis in nonconditioned mice accelerates age-associated cardiac dysfunction 査読有り 国際誌 Open Access

    Wang, Y; Sano, S; Yura, Y; Ke, ZH; Sano, M; Oshima, K; Ogawa, H; Horitani, K; Min, KD; Miura-Yura, E; Kour, A; Evans, MA; Zuriaga, MA; Hirschi, KK; Fuster, JJ; Pietras, EM; Walsh, K

    JCI INSIGHT   5 巻 ( 6 )   2020年3月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Jci Insight  

    Clonal hematopoiesis of indeterminate potential is prevalent in elderly individuals and associated with increased risks of all-cause mortality and cardiovascular disease. However, mouse models to study the dynamics of clonal hematopoiesis and its consequences on the cardiovascular system under homeostatic conditions are lacking. We developed a model of clonal hematopoiesis using adoptive transfer of unfractionated ten-eleven translocation 2-mutant (Tet2-mutant) bone marrow cells into nonirradiated mice. Consistent with age-related clonal hematopoiesis observed in humans, these mice displayed a progressive expansion of Tet2-deficient cells in multiple hematopoietic stem and progenitor cell fractions and blood cell lineages. The expansion of the Tet2-mutant fraction was also observed in bone marrow-derived CCR2<sup>+</sup> myeloid cell populations within the heart, but there was a negligible impact on the yolk sac-derived CCR2- cardiac-resident macrophage population. Transcriptome profiling revealed an enhanced inflammatory signature in the donor-derived macrophages isolated from the heart. Mice receiving Tet2-deficient bone marrow cells spontaneously developed age-related cardiac dysfunction characterized by greater hypertrophy and fibrosis. Altogether, we show that Tet2-mediated hematopoiesis contributes to cardiac dysfunction in a nonconditioned setting that faithfully models human clonal hematopoiesis in unperturbed bone marrow. Our data support clinical findings that clonal hematopoiesis per se may contribute to diminished health span.

    DOI: 10.1172/jci.insight.135204

    Open Access

    Web of Science

    Scopus

    PubMed

  9. Clonal Hematopoiesis: A New Step Linking Inflammation to Heart Failure 査読有り 国際誌 Open Access

    Yura, Y; Sano, S; Walsh, K

    JACC-BASIC TO TRANSLATIONAL SCIENCE   5 巻 ( 2 ) 頁: 196 - 207   2020年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Jacc Basic to Translational Science  

    Heart failure is a common disease with poor prognosis that is associated with cardiac immune cell infiltration and dysregulated cytokine expression. Recently, the clonal expansion of hematopoietic cells with acquired (i.e., nonheritable) DNA mutations, a process referred to as clonal hematopoiesis, has been reported to be associated with cardiovascular diseases including heart failure. Mechanistic studies have shown that leukocytes that harbor these somatic mutations display altered inflammatory characteristics that worsen the phenotypes associated with heart failure in experimental models. In this review, we summarize recent epidemiological and experimental evidence that support the hypothesis that clonal hematopoiesis-mediated immune cell dysfunction contributes to heart failure and cardiovascular disease in general.

    DOI: 10.1016/j.jacbts.2019.08.006

    Open Access

    Web of Science

    Scopus

    PubMed

  10. Endothelial cell-specific redox gene modulation inhibits angiogenesis but promotes B16F0 tumor growth in mice 査読有り 国際誌 Open Access

    Yura, Y; Chong, BSH; Johnson, RD; Watanabe, Y; Tsukahara, Y; Ferran, B; Murdoch, CE; Behring, JB; McComb, ME; Costello, CE; Janssen-Heininger, YMW; Cohen, RA; Bachschmid, MM; Matsui, R

    FASEB JOURNAL   33 巻 ( 12 ) 頁: 14147 - 14158   2019年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:FASEB Journal  

    Glutaredoxin-1 (Glrx) is a small cytosolic enzyme that removes S-glutathionylation, glutathione adducts of protein cysteine residues, thus modulating redox signaling and gene transcription. Although Glrx up-regulation prevented endothelial cell (EC) migration and global Glrx transgenic mice had impaired ischemic vascularization, the effects of cell-specific Glrx overexpression remained unknown. Here, we examined the role of EC-specific Glrx up-regulation in distinct models of angiogenesis; namely, hind limb ischemia and tumor angiogenesis. EC-specific Glrx transgenic (EC-Glrx TG) overexpression in mice significantly impaired EC migration in Matrigel implants and hind limb revascularization after femoral artery ligation. Additionally, ECs migrated less into subcutaneously implanted B16F0 melanoma tumors as assessed by decreased staining of EC markers. Despite reduced angiogenesis, EC-Glrx TG mice unexpectedly developed larger tumors compared with control mice. EC-Glrx TG mice showed higher levels of VEGF-A in the tumors, indicating hypoxia, which may stimulate tumor cells to form vascular channels without EC, referred to as vasculogenic mimicry. These data suggest that impaired ischemic vascularization does not necessarily associate with suppression of tumor growth, and that antiangiogenic therapies may be ineffective for melanoma tumors because of their ability to implement vasculogenic mimicry during hypoxia.—Yura, Y., Chong, B. S. H., Johnson, R. D., Watanabe, Y., Tsukahara, Y., Ferran, B., Murdoch, C. E., Behring, J. B., McComb, M. E., Costello, C. E., Janssen-Heininger, Y. M. W., Cohen, R. A., Bachschmid, M. M., Matsui, R. Endothelial cell-specific redox gene modulation inhibits angiogenesis but promotes B16F0 tumor growth in mice. FASEB J. 33, 14147-14158 (2019). www.fasebj.org.

    DOI: 10.1096/fj.201900786R

    Web of Science

    Scopus

    PubMed

  11. Focused Proteomics Revealed a Novel Rho-kinase Signaling Pathway in the Heart 査読有り Open Access

    Yura Yoshimitsu, Amano Mutsuki, Takefuji Mikito, Bando Tomohiro, Suzuki Kou, Kato Katsuhiro, Hamaguchi Tomonari, Shohag Md. Hasanuzzaman, Takano Tetsuya, Funahashi Yasuhiro, Nakamuta Shinichi, Kuroda Keisuke, Nishioka Tomoki, Murohara Toyoaki, Kaibuchi Kozo

    CELL STRUCTURE AND FUNCTION   41 巻 ( 2 ) 頁: 105 - 120   2016年

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1247/csf.16011

    Open Access

    Web of Science

  12. Mitochondrial transfer from adipose-derived regenerative cells contributes therapeutic angiogenesis in a murine hindlimb ischemia model 査読有り 国際誌 Open Access

    Che, YY; Shimizu, Y; Hayashi, T; Suzuki, J; Pu, ZY; Tsuzuki, K; Narita, S; Yura, Y; Shibata, R; Murohara, T

    ANGIOGENESIS   28 巻 ( 4 ) 頁: 49 - 49   2025年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Angiogenesis  

    Objective: Adipose-derived regenerative cells (ADRCs) are promising cell sources for damaged tissue regeneration. The efficacy of therapeutic angiogenesis with ADRC implantation in patients with critical limb ischemia has been demonstrated in clinical studies. There are several possible mechanisms in this process such as cytokines and microRNA. Recently, cell-to-cell transfer of mitochondria gains more attention in regenerative medicine. However, the role of the mitochondrial transfer mechanism in ADRCs in the regeneration of functional tissue perfusion following ischemic injury remains unclear. In this study, we aimed to investigate whether mitochondrial transfer is a potential mechanism of therapeutic angiogenesis in ADRCs using a murine hindlimb ischemia model. Methods and results: In initial studies, the occurrence of mitochondrial transfer of ADRC to endothelial cells and macrophages in a series of pro-angiogenic effects of ADRC was demonstrated in a mouse model of hindlimb ischemia. Subsequently, we comprehensively elucidated the modes of mitochondrial transfer from ADRCs to HUVECs and macrophages mediated by Connexin43-based gap junctions and tunneling nanotubes using time-lapse confocal microscopy and cell sorting techniques. Furthermore, mitochondrial transfer from ADRCs enhanced mitochondrial biogenesis and angiogenesis in vascular endothelial cells and shifted macrophages toward the M2-phenotype. Notably, partially canceled mitochondrial transfer from ADRCs could impede the angiogenic ability of ADRCs in hind limb ischemia. Conclusions: ADRCs can protect against ischemic limbs, at least in part by mitochondrial transfer via gap junctions and tunneling of nanotubes into injured endothelial cells and macrophages. Additionally, mitochondrial transfer is a potential mechanism for therapeutic angiogenesis with ADRCs in hindlimb ischemia.

    DOI: 10.1007/s10456-025-10001-z

    Open Access

    Web of Science

    Scopus

    PubMed

  13. Safety and efficacy of retreatment with immune checkpoint inhibitors after severe immune-related adverse events 査読有り 国際誌 Open Access

    Mizuno, K; Ito, T; Sawada, T; Kobayashi, T; Iwama, S; Mori, S; Hase, T; Fukami, Y; Furusawa, K; Yura, Y; Morimoto, R; Sajiki, A; Ushida, H; Kato, N; Maruyama, S; Murohara, T; Katsuno, M; Ishii, M; Akiyama, M; Arima, H; Kawashima, H; Ando, Y

    ONCOLOGIST   30 巻 ( 6 )   2025年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Oncologist  

    Background While immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, they can trigger severe immune-related adverse events (irAEs). The safety and efficacy of ICI retreatment after severe irAEs remain poorly understood. Methods We conducted a retrospective analysis of 1271 patients with malignancies treated with ICIs at a university hospital in Japan between September 2014 and June 2023. We evaluated the incidence and characteristics of severe irAEs, defined as grade ≥3, and the safety and efficacy of ICI retreatment. Results Severe irAEs occurred in 222 patients (17.5%). Patients with single endocrinopathies were excluded, and 46 (28.4%) of the remaining 162 patients underwent ICI retreatment. Upon retreatment, 14 patients (30.4%) experienced recurrent or new grade ≥2 irAEs. One patient who experienced hepatotoxicity (grade 3) at initial ICI treatment developed a recurrence (grade 4). Regarding antitumor response, the objective response rate to retreatment was 28.3% (13/46), with 10.9% achieving complete and 17.4% partial response. The median duration of ICI administration after retreatment was 218 days (95% confidence interval [CI]: 84-399). At 1 year after retreatment, 15.4% (95% CI: 6.8-27.4) of patients discontinued due to irAEs, 44.4% (95% CI: 29.7-58.1) due to disease progression, 6.6% (95% CI: 1.7-16.3) completed planned treatment, and 33.4% (95% CI: 20.3-47.2) continued treatment. Conclusions ICI retreatment after severe irAEs demonstrated a manageable safety profile and promising efficacy, even in patients with grade ≥3 irAEs. ICI retreatment may be a viable option for patients with limited alternatives, particularly those showing favorable antitumor responses at initial treatment.

    DOI: 10.1093/oncolo/oyaf120

    Open Access

    Web of Science

    Scopus

    PubMed

  14. Urocortin2 measurement for heart failure assessment 査読有り 国際誌 Open Access

    Inukai, K; Miyashita, K; Kotani, K; Morimoto, R; Kondo, T; Hiraiwa, H; Kazama, S; Yoshida, T; Yoshida, S; Hattori, T; Fukamachi, K; Fukui, N; Kato, K; Yura, Y; Ohashi, K; Ouchi, N; Murohara, T; Okumura, T; Takefuji, M

    SCIENTIFIC REPORTS   15 巻 ( 1 ) 頁: 14381 - 14381   2025年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Scientific Reports  

    Despite the efficacy of many therapies for heart failure, it remains a leading cause of morbidity and mortality worldwide, with many patients progressing to advanced stages of the condition. Since the standard treatment for heart failure includes small-molecule drugs targeting G protein-coupled receptors (GPCRs), GPCRs are still considered novel targets for the diagnosis and treatment of cardiovascular diseases. Corticotropin-releasing hormone receptor 2, a highly expressed GPCR in cardiomyocytes, and its ligand, urocortin2 (UCN2), have been reportedly associated with cardiovascular diseases; however, their clinical significance remains unclear. In this study, a UCN2 measurement assay was developed to measure blood UCN2 levels in patients with heart failure. The assay showed that blood UCN2 values indicated a negative relationship with cardiac ejection fraction in 52 patients with heart failure. Blood UCN2 levels were not correlated with brain natriuretic peptide, a standard marker of heart failure, and were higher in patients with cardiomyopathy than in those with heart failure, suggesting that measuring blood UCN2 levels may be a novel test for assessing the pathophysiology of heart failure.

    DOI: 10.1038/s41598-025-99509-4

    Open Access

    Web of Science

    Scopus

    PubMed

  15. Pemafibrate ameliorates renal injury through induction of FGF21 and ketone body production in male mice 査読有り 国際誌 Open Access

    Takahara, K; Ouchi, N; Takikawa, T; Ozaki, Y; Fang, LX; Kawanishi, H; Tatsumi, M; Yura, Y; Kato, K; Takefuji, M; Murohara, T; Ohashi, K

    PHYSIOLOGICAL REPORTS   13 巻 ( 3 ) 頁: e70135   2025年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Physiological Reports  

    Chronic kidney disease is a life-threatening disease worldwide. PPARα is a crucial transcriptional regulator of lipid metabolism and inflammation. Here, we examine whether a novel selective PPARα modulator, pemafibrate modulates renal injury in a model of unilateral ureteral obstruction (UUO). Administration of pemafibrate to wild-type (WT) mice led to reduction of renal dysfunction and fibrosis after UUO with accompanying increases in plasma levels of fibroblast growth factor (FGF) 21 and ketone body β-hydroxybutyrate (BHB). Treatment of WT mice with FGF21 or BHB precursor resulted in attenuation of renal fibrotic and inflammatory responses after UUO. Treatment of proximal tubular cells with FGF21 or BHB reduced expression of epithelial–mesenchymal transition markers. These findings suggest that pemafibrate could ameliorate renal damage, at least in part, by its abilities to increase the production of FGF21 and BHB.

    DOI: 10.14814/phy2.70135

    Open Access

    Web of Science

    Scopus

    PubMed

  16. <i>Tet2</i>-mediated clonal hematopoiesis modestly improves neurological deficits and is associated with inflammation resolution in the subacute phase of experimental stroke 査読有り 国際誌 Open Access

    Evans, MA; Chavkin, NW; Sano, S; Sun, HN; Sardana, T; Ravi, R; Doviak, H; Wang, Y; Yura, Y; Polizio, AH; Horitani, K; Ogawa, H; Hirschi, KK; Walsh, K

    FRONTIERS IN CELLULAR NEUROSCIENCE   18 巻   頁: 1487867 - 1487867   2024年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Frontiers in Cellular Neuroscience  

    Introduction: Recent work has revealed that clonal hematopoiesis (CH) is associated with a higher risk of numerous age-related diseases, including ischemic stroke, however little is known about whether it influences stroke outcome independent of its widespread effects on cardiovascular disease. Studies suggest that leukocytes carrying CH driver mutations have an enhanced inflammatory profile, which could conceivably exacerbate brain injury after a stroke. Methods: Using a competitive bone marrow transplant model of Tet2-mediated CH, we tested the hypothesis that CH would lead to a poorer outcome after ischemic stroke by augmenting brain inflammation. Stroke was induced in mice by middle cerebral artery occlusion and neurological outcome was assessed at acute (24 h) and subacute (14 d) timepoints. Brains were collected at both time points for histological, immunofluorescence and gene expression assays. Results: Unexpectedly, Tet2-mediated CH had no effect on acute stroke outcome but led to a reduction in neurological deficits during the subacute phase. This improved neurological outcome was associated with lower levels of brain inflammation as evidenced by lower transcript levels of various inflammatory molecules alongside reduced astrogliosis. Discussion: These findings suggest that Tet2-mediated CH may have beneficial effects on outcome after stroke, contrasting with the conventional understanding of CH whereby leukocytes with driver mutations promote disease by exacerbating inflammation.

    DOI: 10.3389/fncel.2024.1487867

    Open Access

    Web of Science

    Scopus

    PubMed

  17. ALPK2 prevents cardiac diastolic dysfunction in heart failure with preserved ejection fraction 査読有り 国際誌 Open Access

    Yoshida, T; Yoshida, S; Inukai, K; Kato, K; Yura, Y; Hattori, T; Taki, K; Enomoto, A; Ohashi, K; Okumura, T; Ouchi, N; Kawase, H; Wettschureck, N; Offermanns, S; Murohara, T; Takefuji, M

    FASEB JOURNAL   38 巻 ( 22 ) 頁: e70192   2024年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:FASEB Journal  

    Protein phosphorylation, controlled by protein kinases, is central to regulating various pathophysiological processes, including cardiac systolic function. The dysregulation of protein kinase activity plays a significant role in the pathogenesis of cardiac systolic dysfunction. While cardiac contraction mechanisms are well documented, the mechanisms underlying cardiac diastole remain elusive. This gap persists owing to the historical focus on systolic dysfunction in heart failure research. Recently, heart failure with preserved ejection fraction (HFpEF), an age-related disease characterized by cardiac diastolic dysfunction, has emerged as a major public health concern. However, its underlying mechanism remains unclear. In this study, we investigated cardiac protein kinases by analyzing the gene expression of 518 protein kinases in human tissues. We identified alpha-kinase 2 (ALPK2) as a novel cardiac-specific atypical kinase and generated tamoxifen-inducible, cardiomyocyte-specific Alpk2-knockout mice and Alpk2-overexpressing mice. Alpk2 deficiency did not affect cardiac systolic dysfunction in the myocardial infarction model or the pressure-overload-induced heart failure model. Notably, cardiomyocyte-specific Alpk2 deficiency exacerbated cardiac diastolic dysfunction induced by aging and in the HFpEF model. Conversely, Alpk2 overexpression increased the phosphorylation of tropomyosin 1, a major regulator that binds myosin to actin, and mitigated cardiac stiffness in HFpEF. This study provides novel evidence that ALPK2 represents a potential therapeutic target for cardiac diastolic dysfunction in HFpEF and age-related cardiac impairments.

    DOI: 10.1096/fj.202402103R

    Open Access

    Web of Science

    Scopus

    PubMed

  18. Protein kinase N promotes cardiac fibrosis in heart failure by fibroblast-to-myofibroblast conversion 査読有り 国際誌 Open Access

    Yoshida, S; Yoshida, T; Inukai, K; Kato, K; Yura, Y; Hattori, T; Enomoto, A; Ohashi, K; Okumura, T; Ouchi, N; Kawase, H; Wettschureck, N; Offermanns, S; Murohara, T; Takefuji, M

    NATURE COMMUNICATIONS   15 巻 ( 1 ) 頁: 7638 - 7638   2024年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Nature Communications  

    Chronic fibrotic tissue disrupts various organ functions. Despite significant advances in therapies, mortality and morbidity due to heart failure remain high, resulting in poor quality of life. Beyond the cardiomyocyte-centric view of heart failure, it is now accepted that alterations in the interstitial extracellular matrix (ECM) also play a major role in the development of heart failure. Here, we show that protein kinase N (PKN) is expressed in cardiac fibroblasts. Furthermore, PKN mediates the conversion of fibroblasts into myofibroblasts, which plays a central role in secreting large amounts of ECM proteins via p38 phosphorylation signaling. Fibroblast-specific deletion of PKN led to a reduction of myocardial fibrotic changes and cardiac dysfunction in mice models of ischemia-reperfusion or heart failure with preserved ejection fraction. Our results indicate that PKN is a therapeutic target for cardiac fibrosis in heart failure.

    DOI: 10.1038/s41467-024-52068-0

    Open Access

    Web of Science

    Scopus

    PubMed

  19. Interplay of the heart, spleen, and bone marrow in heart failure: the role of splenic extramedullary hematopoiesis 査読有り 国際誌 Open Access

    Hiraiwa, H; Yura, Y; Okumura, T; Murohara, T

    HEART FAILURE REVIEWS   29 巻 ( 5 ) 頁: 1049 - 1063   2024年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Heart Failure Reviews  

    Improvements in therapies for heart failure with preserved ejection fraction (HFpEF) are crucial for improving patient outcomes and quality of life. Although HFpEF is the predominant heart failure type among older individuals, its prognosis is often poor owing to the lack of effective therapies. The roles of the spleen and bone marrow are often overlooked in the context of HFpEF. Recent studies suggest that the spleen and bone marrow could play key roles in HFpEF, especially in relation to inflammation and immune responses. The bone marrow can increase production of certain immune cells that can migrate to the heart and contribute to disease. The spleen can contribute to immune responses that either protect or exacerbate heart failure. Extramedullary hematopoiesis in the spleen could play a crucial role in HFpEF. Increased metabolic activity in the spleen, immune cell production and mobilization to the heart, and concomitant cytokine production may occur in heart failure. This leads to systemic chronic inflammation, along with an imbalance of immune cells (macrophages) in the heart, resulting in chronic inflammation and progressive fibrosis, potentially leading to decreased cardiac function. The bone marrow and spleen are involved in altered iron metabolism and anemia, which also contribute to HFpEF. This review presents the concept of an interplay between the heart, spleen, and bone marrow in the setting of HFpEF, with a particular focus on extramedullary hematopoiesis in the spleen. The aim of this review is to discern whether the spleen can serve as a new therapeutic target for HFpEF.

    DOI: 10.1007/s10741-024-10418-6

    Open Access

    Web of Science

    Scopus

    PubMed

  20. Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality 査読有り 国際誌 Open Access

    Sano, S; Horitani, K; Ogawa, H; Halvardson, J; Chavkin, NW; Wang, Y; Sano, M; Mattisson, J; Hata, A; Danielsson, M; Miura-Yura, E; Zaghlool, A; Evans, MA; Fall, T; De Hoyos, HN; Sundström, J; Yura, Y; Kour, A; Arai, Y; Thel, MC; Arai, Y; Mychaleckyj, JC; Hirschi, KK; Forsberg, LA; Walsh, K

    SCIENCE   377 巻 ( 6603 ) 頁: 292 - 297   2022年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Science  

    Hematopoietic mosaic loss of Y chromosome (mLOY) is associated with increased risk of mortality and age-related diseases in men, but the causal and mechanistic relationships have yet to be established. Here, we show that male mice reconstituted with bone marrow cells lacking the Y chromosome display increased mortality and age-related profibrotic pathologies including reduced cardiac function. Cardiac macrophages lacking the Y chromosome exhibited polarization toward a more fibrotic phenotype, and treatment with a transforming growth factor b1–neutralizing antibody ameliorated cardiac dysfunction in mLOY mice. A prospective study revealed that mLOY in blood is associated with an increased risk for cardiovascular disease and heart failure–associated mortality. Together, these results indicate that hematopoietic mLOY causally contributes to fibrosis, cardiac dysfunction, and mortality in men.

    DOI: 10.1126/science.abn3100

    Web of Science

    Scopus

    PubMed

  21. Murine models of clonal haematopoiesis to assess mechanisms of cardiovascular disease 査読有り 国際誌 Open Access

    Wang, Y; Sano, S; Ogawa, H; Horitani, K; Evans, MA; Yura, Y; Miura-Yura, E; Doviak, H; Walsh, K

    CARDIOVASCULAR RESEARCH   118 巻 ( 6 ) 頁: 1413 - 1432   2022年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Cardiovascular Research  

    Clonal haematopoiesis (CH) is a phenomenon whereby somatic mutations confer a fitness advantage to haematopoietic stem and progenitor cells (HSPCs) and thus facilitate their aberrant clonal expansion. These mutations are carried into progeny leucocytes leading to a situation whereby a substantial fraction of an individual's blood cells originate from the HSPC mutant clone. Although this condition rarely progresses to a haematological malignancy, circulating blood cells bearing the mutation have the potential to affect other organ systems as they infiltrate into tissues under both homeostatic and disease conditions. Epidemiological and clinical studies have revealed that CH is highly prevalent in the elderly and is associated with an increased risk of cardiovascular disease and mortality. Recent experimental studies in murine models have assessed the most commonly mutated 'driver' genes associated with CH, and have provided evidence for mechanistic connections between CH and cardiovascular disease. A deeper understanding of the mechanisms by which specific CH mutations promote disease pathogenesis is of importance, as it could pave the way for individualized therapeutic strategies targeting the pathogenic CH gene mutations in the future. Here, we review the epidemiology of CH and the mechanistic work from studies using murine disease models, with a particular focus on the strengths and limitations of these experimental systems. We intend for this review to help investigators select the most appropriate models to study CH in the setting of cardiovascular disease.

    DOI: 10.1093/cvr/cvab215

    Web of Science

    Scopus

    PubMed

  22. Molecular damage in aging 査読有り 国際誌 Open Access

    Gladyshev, VN; Kritchevsky, SB; Clarke, SG; Cuervo, AM; Fiehn, O; de Magalhaes, JP; Mau, T; Maes, M; Moritz, RL; Niedernhofer, LJ; Van Schaftingen, E; Tranah, GJ; Walsh, K; Yura, Y; Zhang, BH; Cummings, SR

    NATURE AGING   1 巻 ( 12 ) 頁: 1096 - 1106   2021年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Nature Aging  

    Cellular metabolism and environmental interactions generate molecular damage affecting all levels of biological organization. Accumulation of this damage over time is thought to have a central role in the aging process. Insufficient attention has been paid to the role of molecular damage in aging-related phenotypes, particularly in humans, in part because of the difficulty in measuring its various forms. Recently, omics approaches have been developed that begin to address this challenge, because they can assess a sizable proportion of age-related damage at the level of small molecules, proteins, RNA, DNA, organelles and cells. This Review describes the concept of molecular damage in aging and discusses its diverse aspects from theoretical models to experimental approaches. Measurement of multiple types of damage enables studies of the role of damage in aging and lays a foundation for testing interventions that reduce the burden of molecular damage, thereby targeting aging.

    DOI: 10.1038/s43587-021-00150-3

    Web of Science

    Scopus

    PubMed

  23. TP53-mediated therapy-related clonal hematopoiesis contributes to doxorubicin-induced cardiomyopathy by augmenting a neutrophil-mediated cytotoxic response 査読有り 国際誌 Open Access

    Sano, S; Wang, Y; Ogawa, H; Horitani, K; Sano, M; Polizio, AH; Kour, A; Yura, Y; Doviak, H; Walsh, K

    JCI INSIGHT   6 巻 ( 13 )   2021年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Jci Insight  

    Therapy-related clonal hematopoiesis (t-CH) is often observed in cancer survivors. This form of clonal hematopoiesis typically involves somatic mutations in driver genes that encode components of the DNA damage response and confer hematopoietic stem and progenitor cells (HSPCs) with resistance to the genotoxic stress of the cancer therapy. Here, we established a model of TP53-mediated t-CH through the transfer of Trp53 mutant HSPCs to mice, followed by treatment with a course of the chemotherapeutic agent doxorubicin. These studies revealed that neutrophil infiltration in the heart significantly contributes to doxorubicin-induced cardiac toxicity and that this condition is amplified in the model of Trp53-mediated t-CH. These data suggest that t-CH could contribute to the elevated heart failure risk that occurs in cancer survivors who have been treated with genotoxic agents.

    DOI: 10.1172/jci.insight.146076

    Open Access

    Web of Science

    Scopus

    PubMed

  24. Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis 査読有り 国際誌 Open Access

    Park, E; Evans, MA; Doviak, H; Horitani, K; Ogawa, H; Yura, Y; Wang, Y; Sano, S; Walsh, K

    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS   2021 巻 ( 171 )   2021年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Journal of Visualized Experiments  

    Clonal hematopoiesis is a prevalent age-associated condition that results from the accumulation of somatic mutations in hematopoietic stem and progenitor cells (HSPCs). Mutations in driver genes, that confer cellular fitness, can lead to the development of expanding HSPC clones that increasingly give rise to progeny leukocytes harboring the somatic mutation. Because clonal hematopoiesis has been associated with heart disease, stroke, and mortality, the development of experimental systems that model these processes is key to understanding the mechanisms that underly this new risk factor. Bone marrow transplantation procedures involving myeloablative conditioning in mice, such as total-body irradiation (TBI), are commonly employed to study the role of immune cells in cardiovascular diseases. However, simultaneous damage to the bone marrow niche and other sites of interest, such as the heart and brain, is unavoidable with these procedures. Thus, our lab has developed two alternative methods to minimize or avoid possible side effects caused by TBI: 1) bone marrow transplantation with irradiation shielding and 2) adoptive BMT to non-conditioned mice. In shielded organs, the local environment is preserved allowing for the analysis of clonal hematopoiesis while the function of resident immune cells is unperturbed. In contrast, the adoptive BMT to non-conditioned mice has the additional advantage that both the local environments of the organs and the hematopoietic niche are preserved. Here, we compare three different hematopoietic cell reconstitution approaches and discuss their strengths and limitations for studies of clonal hematopoiesis in cardiovascular disease.

    DOI: 10.3791/61875

    Web of Science

    Scopus

    PubMed

  25. MAPKによるNpas4のリン酸化は報酬関連の遺伝子発現と行動を制御する 国際誌 Open Access

    船橋 靖広, アリザ アンソニー, 恵美 亮佑, 許 伊凡, 単 偉, 小澤 祥, アハマド リジュワン ウッディン, 呉 夢雅, 高野 哲也, 由良 義光, 黒田 啓介, 永井 拓, 天野 睦紀, 山田 清文, 貝淵 弘三

    日本薬理学会年会要旨集   93 巻 ( 0 ) 頁: 1-YIA-26 - +   2020年

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:公益社団法人 日本薬理学会  

    <p>Dopamine (DA) activates MAPK via PKA/Rap1 in medium spiny neurons (MSNs) expressing the dopamine D1 receptor (D1R)in the nucleus accumbens (NAc), thereby regulating reward-related behavior.However, howMAPKregulates reward-relatedlearning and memory through gene expression is poorly understood. Here, to identify the relevant transcriptional factors, we performed proteomic analysis using affinity beads coated with CREB-binding protein (CBP), a transcriptional coactivator involved in reward-related behavior. We identified more than 400 CBP-interacting proteins, including Neuronal Per Arnt Sim domain protein 4 (Npas4). We found that MAPK phosphorylated Npas4 downstream of PKA, increasing the Npas4-CBP interaction and the transcriptional activity of Npas4 at the brain-derived neurotrophic factor (BDNF) promoter. The deletion of Npas4 in D1R-expressing MSNs impaired cocaine-induced place preference, which was rescued by Npas4-WT but not by a phospho-deficient Npas4 mutant. These observations suggest that MAPK phosphorylates Npas4 in D1R-MSNs and increases transcriptional activity to enhance reward-related learning and memory. (Funahashi et al., Cell Reports, 2019)</p>

    DOI: 10.1254/jpssuppl.93.0_1-yia-26

    Open Access

    Web of Science

    Scopus

    PubMed

    CiNii Research

  26. Protein Kinase N Promotes Stress-Induced Cardiac Dysfunction Through Phosphorylation of Myocardin-Related Transcription Factor A and Disruption of Its Interaction With Actin 査読有り 国際誌 Open Access

    Sakaguchi, T; Takefuji, M; Wettschureck, N; Hamaguchi, T; Amano, M; Kato, K; Tsuda, T; Eguchi, S; Ishihama, S; Mori, Y; Yura, Y; Yoshida, T; Unno, K; Okumura, T; Ishii, H; Shimizu, Y; Bando, YK; Ohashi, K; Ouchi, N; Enomoto, A; Offermanns, S; Kaibuchi, K; Murohara, T

    CIRCULATION   140 巻 ( 21 ) 頁: 1737 - 1752   2019年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Circulation  

    Background: Heart failure is a complex syndrome that results from structural or functional impairment of ventricular filling or blood ejection. Protein phosphorylation is a major and essential intracellular mechanism that mediates various cellular processes in cardiomyocytes in response to extracellular and intracellular signals. The RHOA-associated protein kinase (ROCK/Rho-kinase), an effector regulated by the small GTPase RHOA, causes pathological phosphorylation of proteins, resulting in cardiovascular diseases. RHOA also activates protein kinase N (PKN); however, the role of PKN in cardiovascular diseases remains unclear. Methods: To explore the role of PKNs in heart failure, we generated tamoxifen-inducible, cardiomyocyte-specific PKN1- and PKN2-knockout mice by intercrossing the αMHC-CreERT2 line with Pkn1<sup>flox/flox</sup> and Pkn2<sup>flox/flox</sup> mice and applied a mouse model of transverse aortic constriction- and angiotensin II-induced heart failure. To identify a novel substrate of PKNs, we incubated GST-tagged myocardin-related transcription factor A (MRTFA) with recombinant GST-PKN-catalytic domain or GST-ROCK-catalytic domain in the presence of radiolabeled ATP and detected radioactive GST-MRTFA as phosphorylated MRTFA. Results: We demonstrated that RHOA activates 2 members of the PKN family of proteins, PKN1 and PKN2, in cardiomyocytes of mice with cardiac dysfunction. Cardiomyocyte-specific deletion of the genes encoding Pkn1 and Pkn2 (cmc-PKN1/2 DKO) did not affect basal heart function but protected mice from pressure overload- and angiotensin II-induced cardiac dysfunction. Furthermore, we identified MRTFA as a novel substrate of PKN1 and PKN2 and found that MRTFA phosphorylation by PKN was considerably more effective than that by ROCK in vitro. We confirmed that endogenous MRTFA phosphorylation in the heart was induced by pressure overload- and angiotensin II-induced cardiac dysfunction in wild-type mice, whereas cmc-PKN1/2 DKO mice suppressed transverse aortic constriction- and angiotensin II-induced phosphorylation of MRTFA. Although RHOA-mediated actin polymerization accelerated MRTFA-induced gene transcription, PKN1 and PKN2 inhibited the interaction of MRTFA with globular actin by phosphorylating MRTFA, causing increased serum response factor-mediated expression of cardiac hypertrophy- and fibrosis-associated genes. Conclusions: Our results indicate that PKN1 and PKN2 activation causes cardiac dysfunction and is involved in the transition to heart failure, thus providing unique targets for therapeutic intervention for heart failure.

    DOI: 10.1161/CIRCULATIONAHA.119.041019

    Web of Science

    Scopus

    PubMed

  27. <i>JAK2<SUP>V617F</SUP></i>-Mediated Clonal Hematopoiesis Accelerates Pathological Remodeling in Murine Heart Failure 査読有り 国際誌 Open Access

    Sano, S; Wang, Y; Yura, Y; Sano, MH; Oshima, K; Yang, Y; Katanasaka, Y; Min, KD; Matsuura, S; Ravid, K; Mohi, G; Walsh, K

    JACC-BASIC TO TRANSLATIONAL SCIENCE   4 巻 ( 6 ) 頁: 684 - 697   2019年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Jacc Basic to Translational Science  

    Janus kinase 2 (valine to phenylalanine at residue 617) (JAK2<sup>V617F</sup>) mutations lead to myeloproliferative neoplasms associated with elevated myeloid, erythroid, and megakaryocytic cells. Alternatively these same mutations can lead to the condition of clonal hematopoiesis with no impact on blood cell counts. Here, a model of myeloid-restricted JAK2<sup>V617F</sup> expression from lineage-negative bone marrow cells was developed and evaluated. This model displayed greater cardiac inflammation and dysfunction following permanent left anterior descending artery ligation and transverse aortic constriction. These data suggest that JAK2<sup>V617F</sup>mutations arising in myeloid progenitor cells may contribute to cardiovascular disease by promoting the proinflammatory properties of circulating myeloid cells.

    DOI: 10.1016/j.jacbts.2019.05.013

    Open Access

    Web of Science

    Scopus

    PubMed

  28. Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models 査読有り 国際誌 Open Access

    Sano, S; Wang, Y; Evans, MA; Yura, Y; Sano, M; Ogawa, H; Horitani, K; Doviak, H; Walsh, K

    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS   2019 巻 ( 152 )   2019年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Journal of Visualized Experiments  

    Manipulating genes in hematopoietic stem cells using conventional transgenesis approaches can be time-consuming, expensive, and challenging. Benefiting from advances in genome editing technology and lentivirus-mediated transgene delivery systems, an efficient and economical method is described here that establishes mice in which genes are manipulated specifically in hematopoietic stem cells. Lentiviruses are used to transduce Cas9-expressing lineage-negative bone marrow cells with a guide RNA (gRNA) targeting specific genes and a red fluorescence reporter gene (RFP), then these cells are transplanted into lethally-irradiated C57BL/6 mice. Mice transplanted with lentivirus expressing non-targeting gRNA are used as controls. Engraftment of transduced hematopoietic stem cells are evaluated by flow cytometric analysis of RFP-positive leukocytes of peripheral blood. Using this method, ~90% transduction of myeloid cells and ~70% of lymphoid cells at 4 weeks after transplantation can be achieved. Genomic DNA is isolated from RFP-positive blood cells, and portions of the targeted site DNA are amplified by PCR to validate the genome editing. This protocol provides a high-throughput evaluation of hematopoiesis-regulatory genes and can be extended to a variety of mouse disease models with hematopoietic cell involvement.

    DOI: 10.3791/59977

    Web of Science

    Scopus

    PubMed

  29. Wnt5a-Mediated Neutrophil Recruitment Has an Obligatory Role in Pressure Overload-Induced Cardiac Dysfunction 査読有り 国際誌 Open Access

    Wang, Y; Sano, S; Oshima, K; Sano, M; Watanabe, Y; Katanasaka, Y; Yura, Y; Jung, C; Anzai, A; Swirski, FK; Gokce, N; Walsh, K

    CIRCULATION   140 巻 ( 6 ) 頁: 487 - 499   2019年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Circulation  

    Background: Although the complex roles of macrophages in myocardial injury are widely appreciated, the function of neutrophils in nonischemic cardiac pathology has received relatively little attention. Methods: To examine the regulation and function of neutrophils in pressure overload-induced cardiac hypertrophy, mice underwent treatment with Ly6G antibody to deplete neutrophils and then were subjected to transverse aortic constriction. Results: Neutrophil depletion diminished transverse aortic constriction-induced hypertrophy and inflammation and preserved cardiac function. Myeloid deficiency of Wnt5a, a noncanonical Wnt, suppressed neutrophil infiltration to the hearts of transverse aortic constriction-treated mice and produced a phenotype that was similar to the neutropenic conditions. Conversely, mice overexpressing Wnt5a in myeloid cells displayed greater hypertrophic growth, inflammation, and cardiac dysfunction. Neutrophil depletion reversed the Wnt5a overexpression-induced cardiac pathology and eliminated differences in cardiac parameters between wild-type and myeloid-specific Wnt5a transgenic mice. Conclusions: These findings reveal that Wnt5a-regulated neutrophil infiltration has a critical role in pressure overload-induced heart failure.

    DOI: 10.1161/CIRCULATIONAHA.118.038820

    Web of Science

    Scopus

    PubMed

  30. Effects of aging and sex on redox-regulation of ischemic vascularization 査読有り

    Perez, BF; Tsukahara, Y; Yura, Y; Bachschmid, MM; Matsui, R

    FREE RADICAL BIOLOGY AND MEDICINE   112 巻   頁: 51 - 52   2017年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.freeradbiomed.2017.10.068

    Web of Science

  31. Differential regulation of ischemic limb vascularization and tumor growth by endothelial glutaredoxin-1 査読有り

    Yura, Y; Johnson, R; Watanabe, Y; Tsukahara, Y; Ferran, BP; Murdoch, C; van der Velden, J; Bachschmid, MM; Heininger, YJ; Matsui, R

    FREE RADICAL BIOLOGY AND MEDICINE   112 巻   頁: 38 - 39   2017年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.freeradbiomed.2017.10.050

    Web of Science

  32. Discovery of long-range inhibitory signaling to ensure single axon formation 査読有り 国際誌 Open Access

    Takano, T; Wu, MY; Nakamuta, S; Naoki, H; Ishizawa, N; Namba, T; Watanabe, T; Xu, CD; Hamaguchi, T; Yura, Y; Amano, M; Hahn, KM; Kaibuchi, K

    NATURE COMMUNICATIONS   8 巻 ( 1 ) 頁: 33 - 33   2017年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Nature Communications  

    A long-standing question in neurodevelopment is how neurons develop a single axon and multiple dendrites from common immature neurites. Long-range inhibitory signaling from the growing axon is hypothesized to prevent outgrowth of other immature neurites and to differentiate them into dendrites, but the existence and nature of this inhibitory signaling remains unknown. Here, we demonstrate that axonal growth triggered by neurotrophin-3 remotely inhibits neurite outgrowth through long-range Ca<sup>2+</sup> waves, which are delivered from the growing axon to the cell body. These Ca<sup>2+</sup> waves increase RhoA activity in the cell body through calcium/calmodulin-dependent protein kinase I. Optogenetic control of Rho-kinase combined with computational modeling reveals that active Rho-kinase diffuses to growing other immature neurites and inhibits their outgrowth. Mechanistically, calmodulin-dependent protein kinase I phosphorylates a RhoA-specific GEF, GEF-H1, whose phosphorylation enhances its GEF activity. Thus, our results reveal that long-range inhibitory signaling mediated by Ca<sup>2+</sup> wave is responsible for neuronal polarization.

    DOI: 10.1038/s41467-017-00044-2

    Open Access

    Web of Science

    Scopus

    PubMed

  33. Dopamine-induced phosphorylation of NPAS4 through MAPK regulates reward-related learning and memory 査読有り

    Yasuhiro, F; Ariza, A; Wei, S; Kozawa, S; Okuda, K; Suzuki, K; Takano, T; Yura, Y; Kuroda, K; Nagai, T; Kaibuchi, K

    JOURNAL OF PHARMACOLOGICAL SCIENCES   133 巻 ( 3 ) 頁: S216 - S216   2017年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Web of Science

  34. Identification of protein kinase substrates by the kinase-interacting substrate screening (KISS) approach 査読有り 国際誌

    Amano M., Nishioka T., Yura Y., Kaibuchi K.

    Current Protocols in Cell Biology   72 巻   頁: 14.16.1-14.16.12 - 12   2016年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Current Protocols in Cell Biology  

    Identifying the substrates of protein kinases to understand their modes of action has been undertaken by various approaches and remains an ongoing challenge. Phosphoproteomic technologies have accelerated the accumulation of data concerning protein phosphorylation and have uncovered vast numbers of phosphorylation sites in vivo. In this unit, a novel in vitro screening approach for protein kinase substrates is presented, based on protein-protein interaction and mass spectrometry-based phosphoproteomic technology.

    DOI: 10.1002/cpcb.8

    Scopus

    PubMed

  35. Focused proteomics revealed a novel Rho-kinase signaling pathway in the heart Open Access

    Yura Y., Amano M., Takefuji M., Bando T., Suzuki K., Kato K., Hamaguchi T., Shohag M.H., Takano T., Funahashi Y., Nakamuta S., Kuroda K., Nishioka T., Murohara T., Kaibuchi K.

    Cell Structure and Function   41 巻 ( 2 ) 頁: 105 - 120   2016年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:日本細胞生物学会  

    Protein phosphorylation plays an important role in the physiological regulation of cardiac function. Myocardial contraction and pathogenesis of cardiac diseases have been reported to be associated with adaptive or maladaptive protein phosphorylation; however, phosphorylation signaling in the heart is not fully elucidated. We recently developed a novel kinase-interacting substrate screening (KISS) method for exhaustive screening of protein kinase substrates, using mass spectrometry and affinity chromatography. First, we examined protein phosphorylation by extracellular signal-regulated kinase (ERK) and protein kinase A (PKA), which has been relatively well studied in cardiomyocytes. The KISS method showed that ERK and PKA mediated the phosphorylation of known cardiac-substrates of each kinase such as Rps6ka1 and cTnI, respectively. Using this method, we found about 330 proteins as Rho-kinase-mediated substrates, whose substrate in cardiomyocytes is unknown. Among them, CARP/Ankrd1, a muscle ankyrin repeat protein, was confirmed as a novel Rho-kinasemediated substrate. We also found that non-phosphorylatable form of CARP repressed cardiac hypertrophyrelated gene Myosin light chain-2v (MLC-2v) promoter activity, and decreased cell size of heart derived H9c2 myoblasts more efficiently than wild type-CARP. Thus, focused proteomics enable us to reveal a novel signaling pathway in the heart.

    DOI: 10.1247/csf.16011

    Open Access

    Scopus

    PubMed

    CiNii Research

  36. Novel substrates for Rho kinase in the heart 査読有り

    Yura, Y; Amano, M; Kaibuchi, K

    JOURNAL OF PHARMACOLOGICAL SCIENCES   128 巻 ( 3 ) 頁: S101 - S101   2015年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Web of Science

  37. Kinase-interacting substrate screening is a novel method to identify kinase substrates 査読有り 国際誌 Open Access

    Amano, M; Hamaguchi, T; Shohag, MH; Kozawa, K; Kato, K; Zhang, XJ; Yura, Y; Matsuura, Y; Kataoka, C; Nishioka, T; Kaibuchi, K

    JOURNAL OF CELL BIOLOGY   209 巻 ( 6 ) 頁: 895 - 912   2015年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Journal of Cell Biology  

    Protein kinases play pivotal roles in numerous cellular functions; however, the specific substrates of each protein kinase have not been fully elucidated. We have developed a novel method called kinase-interacting substrate screening (KISS). Using this method, 356 phosphorylation sites of 140 proteins were identified as candidate substrates for Rho-associated kinase (Rho-kinase/ROCK2), including known substrates. The KISS method was also applied to additional kinases, including PKA, MAPK1, CDK5, CaMK1, PAK7, PKN, LYN, and FYN, and a lot of candidate substrates and their phosphorylation sites were determined, most of which have not been reported previously. Among the candidate substrates for Rho-kinase, several functional clusters were identified, including the polarity-associated proteins, such as Scrib. We found that Scrib plays a crucial role in the regulation of subcellular contractility by assembling into a ternary complex with Rho-kinase and Shroom2 in a phosphorylation-dependent manner. We propose that the KISS method is a comprehensive and useful substrate screen for various kinases.

    DOI: 10.1083/jcb.201412008

    Web of Science

    Scopus

    PubMed

  38. New-onset atrial fibrillation may be a more important predictor of cardiac mortality in acute myocardial infarction patients than preexisting atrial fibrillation 査読有り 国際誌

    Morishima, I; Tomomatsu, T; Okumura, K; Sone, T; Tsuboi, H; Morita, Y; Inoue, Y; Yoshida, R; Yura, Y; Murohara, T

    INTERNATIONAL JOURNAL OF CARDIOLOGY   187 巻 ( 1 ) 頁: 475 - 477   2015年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:International Journal of Cardiology  

    DOI: 10.1016/j.ijcard.2015.03.379

    Web of Science

    Scopus

    PubMed

  39. In vivo Screening for Substrates of Protein Kinase A Using a Combination of Proteomic Approaches and Pharmacological Modulation of Kinase Activity 査読有り 国際誌

    Hamaguchi Tomonari, Nakamuta Shinichi, Funahashi Yasuhiro, Takano Tetsuya, Nishioka Tomoki, Shohag Md. Hasanuzzaman, Yura Yoshimitsu, Kaibuchi Kozo, Amano Mutsuki

    CELL STRUCTURE AND FUNCTION   40 巻 ( 1 ) 頁: 1 - 12   2015年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Web of Science

  40. In vivo Screening for Substrates of Protein Kinase A Using a Combination of Proteomic Approaches and Pharmacological Modulation of Kinase Activity

    Hamaguchi T., Nakamuta S., Funahashi Y., Takano T., Nishioka T., Shohag M.H., Yura Y., Kaibuchi K., Amano M.

    Cell Structure and Function   40 巻 ( 1 ) 頁: 1 - 12   2015年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:日本細胞生物学会  

    Protein kinase A (PKA) is a serine/threonine kinase whose activity depends on the levels of cyclic AMP (cAMP). PKA plays essential roles in numerous cell types such as myocytes and neurons. Numerous substrate screens have been attempted to clarify the entire scope of the PKA signaling cascade, but it is still underway. Here, we performed a comprehensive screen that consisted of immunoprecipitation and mass spectrometry, with a focus on the identification of PKA substrates. The lysate of HeLa cells treated with Forskolin (FSK)/3-isobutyl methyl xanthine (IBMX) and/or H-89 was subjected to immunoprecipitation using anti-phospho-PKA substrate antibody. The identity of the phosophoproteins and phosphorylation sites in the precipitants was determined using liquid chromatography tandem mass spectrometry (LC/MS/MS). We obtained 112 proteins as candidate substrates and 65 candidate sites overall. Among the candidate substrates, Rho-kinase/ ROCK2 was confirmed to be a novel substrate of PKA both in vitro and in vivo. In addition to Rho-kinase, we found more than a hundred of novel candidate substrates of PKA using this screen, and these discoveries provide us with new insights into PKA signaling.

    DOI: 10.1247/csf.14014

    Scopus

    PubMed

    CiNii Research

  41. Phosphoproteomic Analysis Using the WW and FHA Domains as Biological Filters 査読有り 国際誌

    Shohag Md. Hasanuzzaman, Nishioka Tomoki, Ahammad Rijwan Uddin, Nakamuta Shinichi, Yura Yoshimitsu, Hamaguchi Tomonari, Kaibuchi Kozo, Amano Mutsuki

    CELL STRUCTURE AND FUNCTION   40 巻 ( 2 ) 頁: 95 - 104   2015年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Web of Science

  42. Phosphoproteomic analysis using the WW and FHA domains as biological filters

    Shohag M.H., Nishioka T., Ahammad R.U., Nakamuta S., Yura Y., Hamaguchi T., Kaibuchi K., Amano M.

    Cell Structure and Function   40 巻 ( 2 ) 頁: 95 - 104   2015年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:日本細胞生物学会  

    Protein phosphorylation plays a key role in regulating nearly all intracellular biological events. However, poorly developed phospho-specific antibodies and low phosphoprotein abundance make it difficult to study phosphoproteins. Cellular protein phosphorylation data have been obtained using phosphoproteomic approaches, but the detection of low-abundance or fast-cycling phosphorylation sites remains a challenge. Enrichment of phosphoproteins together with phosphopeptides may greatly enhance the spectrum of low-abundance but biologically important phosphoproteins. Previously, we used 14-3-3ζ to selectively enrich for HeLa cell lysate phosphoproteins. However, because 14-3-3 does not isolate phosphoproteins lacking the 14-3-3-binding motif, we looked for other domains that could complementarily enrich for phosphoproteins. We here assessed and characterized the phosphoprotein binding domains Pinl-WW, CHEK2-FHA, and DLG1-GK Using a strategy based on affinity chromatography, phosphoproteins were collected from the lysates of HeLa cells treated with phosphatase inhibitor or cAMP activator. We identified different subsets of phosphoproteins associated with WW or FHA after calyculin A, okadaic acid, or forskolin treatment. Our Kinase-Oriented Substrate Screening (KiOSS) method, which used phosphoprotein-binding domains, showed that WW and FHA are applicable and useful for the identification of novel phospho-substrates for kinases and can therefore be used as biological filters for comprehensive phosphoproteome analysis.

    DOI: 10.1247/csf.15004

    Scopus

    PubMed

    CiNii Research

  43. Novel substrates of Rho kinase in the heart 査読有り

    Yura, Y; Bando, T; Amano, M; Kaibuchi, K

    MOLECULAR BIOLOGY OF THE CELL   25 巻   2014年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Web of Science

  44. RhoGEF-mediated vasoconstriction in hypertension 査読有り 国際誌 Open Access

    Takefuji, M; Yura, Y; Kaibuchi, K; Murohara, T

    HYPERTENSION RESEARCH   36 巻 ( 11 ) 頁: 930 - 931   2013年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Hypertension Research  

    DOI: 10.1038/hr.2013.101

    Web of Science

    Scopus

    PubMed

▼全件表示

書籍等出版物 4

  1. 生体の科学 特集 新組織学シリーズⅥ:心臓 Ⅱ.心臓と臓器連関 心臓とクローン性造血

    由良義充( 担当: 分担執筆)

    株式会社医学書院   2025年12月 

     詳細を見る

    担当ページ:76 巻 ( 6 ) 頁: 592 - 596   記述言語:日本語 著書種別:学術書

  2. Therapy Related Clonal hematopoiesis 査読有り 国際共著

    Yoshimitsu Yura( 担当: 分担執筆 ,  範囲: Translational Research in Cardio-Oncology)

    Elsevier  2022年7月 

     詳細を見る

    総ページ数:335-528   担当ページ:349-359   記述言語:英語 著書種別:学術書

  3. BIOClinica

    由良 義充

    北隆館  2023年 

     詳細を見る

    総ページ数:5  

    CiNii Research

  4. Therapy Related Clonal hematopoiesis

    Yoshimitsu Yura, Jesse D. Cochran, Kenneth Walsh( 担当: 分担執筆 ,  範囲: Translational Research in Cardio-Oncology)

    2022年7月  ( ISBN:9780323987479

MISC 13

  1. クローン性造血と心血管疾患のかかわり

    由良義充  

    心臓57 巻 ( 2 )   2025年

     詳細を見る

  2. 老化に潜む脅威:クローン性造血が引き起こす心臓血管病

    由良義充  

    日本老年医学会雑誌(Web)61 巻   2024年

     詳細を見る

  3. クローン性造血と心血管疾患:新規診断及び治療的アプローチの可能性を目指して

    由良義充  

    日本循環器学会学術集会(Web)88th 巻   2024年

     詳細を見る

  4. クローン性造血が心血管病に与える影響の解明

    由良義充  

    日本応用酵素協会誌 ( 58 )   2024年

     詳細を見る

  5. クローン性造血:HFpEF病態を加速させる隠れた要因

    由良義充  

    月刊Precision Medicine7 巻 ( 14 )   2024年

     詳細を見る

  6. がんに合併する心血管病の機序と病態,疫学 クローン性造血 がんと心血管疾患の新しいつながり:がん治療関連クローン性造血

    由良義充  

    日本臨床82 巻   2024年

     詳細を見る

  7. DNA損傷応答遺伝子の変異によるクローン性造血が心臓血管病に与える影響の解明

    由良義充  

    心臓56 巻 ( 12 )   2024年

     詳細を見る

  8. クローン性造血と生活習慣病 4 がんと心血管疾患の新しいつながり:がん治療関連クローン性造血

    由良義充  

    Bio Clinica38 巻 ( 5 )   2023年

     詳細を見る

  9. クローン性造血と心血管疾患-新しいゲノム医療の可能性-

    由良義充  

    脈管学(Web)63 巻 ( supplement )   2023年

     詳細を見る

  10. クローン性造血と心臓血管病について

    由良義充  

    日本血管生物医学会学術集会プログラム・抄録集31st (CD-ROM) 巻   2023年

     詳細を見る

  11. クローン性造血が心血管病に与える影響の解明

    由良義充  

    日本応用酵素協会誌 ( 57 )   2023年

     詳細を見る

  12. クローン性造血が大動脈瘤を進展させる機序の解明

    由良義充  

    循環器病研究振興財団バイエル循環器病研究助成業績報告集(Web)2023 巻   2023年

     詳細を見る

  13. がんと心血管疾患の新しいつながり:がん治療関連クローン性造血

    由良義充  

    日本腫瘍循環器学会学術集会抄録集(Web)6th 巻   2023年

     詳細を見る

▼全件表示

講演・口頭発表等 8

  1. Clonal Hematopoiesis in Patients with Cancer -A new potential link between Cancer and Cardiovascular disease 招待有り

    Yoshimitsu Yura

    JCS2023 FUKUOKA Annual Scientific Meeting  2023年3月11日  Japanese Circulation Society

     詳細を見る

    記述言語:英語   会議種別:口頭発表(招待・特別)  

    開催地:Fukuoka   国名:日本国  

  2. Clonal Hematopoiesis in Cardiovascular Disease-Exploring the potential for new diagnostic and therapeutic approaches- 招待有り

    Yoshimitsu Yura

    2024年3月8日 

     詳細を見る

    開催年月日: 2024年3月

    記述言語:英語   会議種別:シンポジウム・ワークショップ パネル(指名)  

    国名:日本国  

  3. Differential regulation of ischemic limb vascularization and tumor growth by endothelial glutaredoxin-1 招待有り 国際会議

    Yura Yoshimitsu, Johnson Ryan, Watanabe Yosuke, Tsukahara Yuko, Ferran Beatriz Perez, Murdoch Colin, van der Velden Jos, Bachschmid Markus Michael, Heininger Yvonne Janssen, Matsui Reiko

    FREE RADICAL BIOLOGY AND MEDICINE  2017年11月 

     詳細を見る

    記述言語:英語   会議種別:口頭発表(一般)  

  4. Novel substrates of Rho kinase in the heart 国際会議

    Yura Y., Bando T., Amano M., Kaibuchi K.

    MOLECULAR BIOLOGY OF THE CELL  2014年12月 

     詳細を見る

    記述言語:英語   会議種別:ポスター発表  

  5. Novel substrates for Rho kinase in the heart 国際会議

    Yura Yoshimitsu, Amano Mutsuki, Kaibuchi Kozo

    JOURNAL OF PHARMACOLOGICAL SCIENCES  2015年7月 

     詳細を見る

    記述言語:英語   会議種別:口頭発表(一般)  

  6. The Therapy-related Clonal Hematopoiesis Driver Gene Ppm1d Promotes Inflammation and Non-ischemic Heart Failure in a Murine Model 国際会議

    Yoshimitsu Yura

    American Heart Association Scientific Sessions 

     詳細を見る

    記述言語:英語   会議種別:口頭発表(一般)  

    国名:アメリカ合衆国  

  7. Focused proteomics revealed a novel Rho-kinase signaling pathway in the heart 国際会議

    International Vascular Biology Meeting  2016年  North American Vascular Biology Organization

     詳細を見る

    記述言語:英語   会議種別:ポスター発表  

    開催地:Boston, Massachusetts   国名:アメリカ合衆国  

  8. Effects of aging and sex on redox-regulation of ischemic vascularization 国際会議

    Perez Beatriz Ferran, Tsukahara Yuko, Yura Yoshimitsu, Bachschmid Markus M., Matsui Reiko

    FREE RADICAL BIOLOGY AND MEDICINE  2017年11月 

     詳細を見る

    記述言語:英語   会議種別:口頭発表(一般)  

▼全件表示

共同研究・競争的資金等の研究課題 11

  1. クローン性造血を介した加齢性心血管病の病態解明

    2023年4月 - 2030年3月

    創発的研究支援事業 

    由良 義充

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

  2. クローン性造血に着目した心収縮能が保たれた心不全の病態解明

    2023年4月 - 2024年3月

    公益財団法人持田記念医学薬学振興財団研究助成 

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:3000000円 ( 直接経費:3000000円 )

  3. 造血幹細胞における体細胞変異が加齢性心臓病に与える影響の解明

    2023年4月 - 2024年3月

    公益財団法人鈴木謙三記念医科学応用研究財団 調査研究助成 

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

  4. クローン性造血を介した心収縮能の保たれた心不全病態の解明

    2022年10月 - 2024年9月

    三菱財団自然科学研究 

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:4000000円 ( 直接経費:40000000円 )

  5. クローン性造血による新型コロナウイルス感染症に伴う心筋炎発症メカニズムの解明

    2022年10月 - 2024年9月

    第20回榊原記念研究助成 

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:2000000円

  6. DNA傷害応答遺伝子におけるクローン性造血が心血管疾患に与える影響の解明

    2022年10月 - 2023年3月

    医療分野国際科学技術共同研究開発推進事業 

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:3030000円 ( 直接経費:2310000円 、 間接経費:693000円 )

  7. クローン性造血を介したHFpEF病態の解明

    2022年4月 - 2023年3月

    堀科学芸術振興財団研究費助成 

      詳細を見る

    担当区分:研究代表者 

  8. 心収縮能が保たれた心不全の病態にクローン性造血が与える影響の検討

    2022年4月 - 2023年3月

    公益財団法人健康科学財団研究助成 

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:500000円 ( 直接経費:500000円 )

  9. 高齢者に高頻度に認める心収縮能が保たれた心不全の病態にクローン性造血が与える影響の検討

    2022年4月 - 2023年3月

    中京⻑寿医療研究推進財団医学研究助成 

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:500000円 ( 直接経費:500000円 )

  10. クローン性造血に着目した小児がん治療後の心不全発症のメカニズムの解明

    2021年12月 - 現在

    未成年心臓血管病の学究等に対する奨励金 

  11. クローン性造血が血管新生に与える影響の検討

    2021年6月 - 2022年5月

    Vascular BiologyInnovationに関する研究助成 

      詳細を見る

    担当区分:研究代表者 

▼全件表示

科研費 16

  1. ヒト心筋疾患におけるクローン性造血に着目した新規診断・治療法の開発基盤研究

    研究課題/研究課題番号:24K11266  2024年4月 - 2027年3月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    奥村 貴裕, 風間 信吾, 由良 義充, 風間 信吾, 由良 義充

      詳細を見る

    担当区分:研究分担者 

    本研究は、心筋疾患患者におけるクローン性造血を評価し、血行動態や心不全重症度、心リモデリング、予後との関連を検討することで、心筋疾患の新しい診断および治療法の開発、発症予防への臨床応用に展開するための研究基盤を確立することを目的とする。
    本年度は、これまでのわが国および海外の研究報告を広範に調査した。その結果、心筋疾患のなかでも、高齢化とともに患者数が激増しつつある、トランスサイレチン型心アミロイドーシス患者に焦点を絞ることにした。特に本疾患とクローン性造血の関連についての既報告が少なく、新規性の高い研究であると判断された。
    探索的単施設前向き観察研究を実施するための準備として、症例の探索と事前予備調査を行った。本施設において治療中のトランスサイレチン心アミロイドーシス患者を調査した結果、遺伝型トランスサイレチン心アミロイドーシス患者26例、野生型トランスサイレチンアミロイドーシス患者128例が同定された。遺伝型における変異内訳は、V30M変異23例、V122I変異1例、V121A変異1例、P43S変異1例であった。
    治療状況としては、全144例中126例でタファミジス投与、19例でブトリシラン投与がなされていた。これら患者群における治療反応性とクローン性造血の関連を評価することで、新たな治療ターゲットの同定につながる可能性がある。
    今後、生命倫理委員会における研究実施承認後、各患者におけるクローン性造血の評価を進めていく予定である。

  2. クローン性造血が心血管病を修飾する機構の解明

    研究課題/研究課題番号:24K19026  2024年4月 - 2026年3月

    日本学術振興会  科学研究費助成事業  若手研究

    由良 義充

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:4680000円 ( 直接経費:3600000円 、 間接経費:1080000円 )

    私たちの骨髄の中には造血幹細胞が存在し、生涯にわたって必要な血球を生み出している。しかし、後天的に遺伝子変異を起こした造血幹細胞が加齢とともに骨髄の中で増殖する現象“クローン性造血”は、心血管疾患の危険因子であることが近年になって明らかとなった。一方で、クローン性造血が心血管疾患を引き起こす仕組みについては十分にわかっておらず、クローン性造血を標的とした心血管病の治療は実現していない。本研究では変異免疫細胞が心臓を構成する遺伝子変異を有さない細胞群に作用して臓器の変化を引き起こす機構に焦点を当て、心血管病の新しい病態機序を明らかにする。

  3. クローン性造血を介した加齢性心血管病の病態解明

    2023年4月 - 2029年

    科学技術振興機構  戦略的な研究開発の推進 創発的研究支援事業 

    由良 義充

      詳細を見る

    担当区分:研究代表者 

    私たちの骨髄には血液細胞の源となる造血幹細胞が存在しますが、歳をとるにつれて遺伝子の異常をもった造血幹細胞が増えることが知られています。この状態はクローン性造血と呼ばれますが、近年になって心血管病の原因となるという驚くべき知見が報告されました。本研究ではクローン性造血に着目して、未解明の心血管病の仕組みを解き明かし、将来の診断・治療にイノベーションを起こすことを目標とします。

  4. クローン性造血に着目した心収縮能が保たれた心不全病態の解明

    2023年4月 - 2025年3月

    公益財団法人MSD生命科学財団  生活習慣病領域若手研究 

      詳細を見る

    担当区分:研究代表者 

  5. DNA損傷応答遺伝子の変異によるクローン性造血が心臓血管病に与える影響の解明

    2023年4月 - 2024年3月

    日本心臓財団  第48回日本心臓財団研究奨励 

      詳細を見る

    担当区分:研究代表者 

  6. 造血幹細胞における体細胞変異が加齢性心臓病に与える影響の解明

    2023年4月 - 2024年3月

    公益財団法人鈴木謙三記念医科学応用研究財団  調査研究助成 

      詳細を見る

    担当区分:研究代表者 

  7. クローン性造血による炎 症性サイトカイン制御不全が心収縮能の保たれた心不全に与える影響の解明

    2023年4月 - 2024年3月

    公益財団法人興和生命科学振興財団  研究助成 

      詳細を見る

    担当区分:研究代表者 

  8. クローン性造血による新型コロナウイルス感染症に伴う心筋炎発症メカニズムの解明

    2022年10月 - 2024年9月

    榊原記念財団  第20回榊原記念研究助成 

      詳細を見る

    担当区分:研究代表者 

  9. クローン性造血を介した心収縮能の保たれた心不全病態の解明

    2022年10月 - 2024年9月

    公益財団法人 三菱財団  三菱財団自然科学研究助成 

      詳細を見る

    担当区分:研究代表者 

  10. DNA傷害応答遺伝子におけるクローン性造血が心血管疾患に与える影響の解明

    2022年10月 - 2023年3月

    日本医療研究開発機構  医療分野国際科学技術共同研究開発推進事業 

      詳細を見る

    担当区分:研究代表者 

  11. クローン性造血がHFpEF病態を修飾するメカニズムの解明

    研究課題/研究課題番号:22K16136  2022年4月 - 2024年3月

    日本学術振興会  科学研究費助成事業 若手研究  若手研究

    由良 義充

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:4550000円 ( 直接経費:3500000円 、 間接経費:1050000円 )

    心収縮機能が保たれた心不全(HFpEF)は、有効な治療薬が限られる難治性疾患である。本研究では、体細胞変異を持つ造血幹細胞が骨髄で増殖した状態「クローン性造血」が、HFpEFに与える影響を実験的に検証した。ヒトのクローン性造血を模したモデルマウスを用いた解析の結果、クローン性造血は免疫細胞の機能変化を介してHFpEF病態を悪化させる可能性が示唆された。

  12. がん治療関連クローン性造血に着目した小児がん治療後の心不全発症メカニズムの解明

    2022年4月 - 2023年3月

    公益財団法人宮田心臓病研究振興基金  未成年心臓血管病の学究等に対する奨励金 

      詳細を見る

    担当区分:研究代表者 

  13. 高齢者に高頻度に認める心収縮能が保たれた心不全の病態にクローン性造血が与える影響の検討

    2022年4月 - 2023年3月

    一般財団法人 中京長寿医療研究推進財団  研究助成 

      詳細を見る

    担当区分:研究代表者 

  14. 心収縮能が保たれた心不全の病態にクローン性造血が与える影響の検討

    2022年4月 - 2023年3月

    公益財団法人健康科学財団  研究助成 

      詳細を見る

    担当区分:研究代表者 

  15. クローン性造血を介したHFpEF病態の解明

    2022年4月 - 2023年3月

    堀科学芸術振興財団  研究助成 

      詳細を見る

    担当区分:研究代表者 

  16. クローン性造血が血管新生に与える影響の検討

    2022年4月 - 2023年3月

    日本応用酵素財団財団  VBIC研究助成金 

      詳細を見る

    担当区分:研究代表者 

▼全件表示

 

担当経験のある科目 (本学) 1

  1. 内科 (臨床実習Ⅰ)

    2023